Streetbeat News

Earnings

OPFI

OppFi (NYSE:OPFI) is scheduled to release its quarterly earnings report on March 7, 2024, with analysts expecting an EPS of $0.07. The company's past performance shows a consistent beat on EPS estimates, leading to positive stock price movements. Shares are currently trading at $3.37, reflecting an 81.54% increase over the last 52 weeks. Investors are advised to pay attention to the earnings guidance for future quarters.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:02 pm

ALIM

Alimera Sciences (NASDAQ:ALIM) is scheduled to release its quarterly earnings report on March 7, 2024, with analysts expecting an EPS of $0.00. The company's past earnings performance shows a mix of hits and misses, with the share price reacting accordingly. Shares have risen 92.42% over the last 52 weeks, indicating a positive outlook from long-term shareholders. Investors will be keenly watching for not just the earnings outcome but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:02 pm

NCSM

NCS Multistage Holdings (NASDAQ:NCSM) is scheduled to release its quarterly earnings report on March 7, 2024, with an expected EPS of $1.18. Historical performance shows a pattern of share price movement post-earnings announcement, with a notable 4.75% drop after missing EPS last quarter. Over the past year, NCSM shares have declined by 38.84%, indicating potential concern among long-term investors as they await this earnings release.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:02 pm

AMTX

Aemetis (NASDAQ:AMTX) is scheduled to release its quarterly earnings report on March 7, 2024, with an estimated EPS of $-0.34. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Aemetis's stock performance has been generally positive over the last year, with a 12.23% increase, despite mixed past earnings performances.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:01 pm

ONCT

Oncternal Therapeutics (NASDAQ:ONCT) is scheduled to release its quarterly earnings report on March 7, 2024, with an expected EPS of $-3.07. Historical data shows a mixed reaction to past earnings, with the stock price fluctuating based on actual EPS outcomes and guidance provided. The company's stock has declined by 44.52% over the last year, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:01 pm

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to release its quarterly earnings report on March 7, 2024, with analysts expecting an EPS of $-0.49. The company's past performance shows a mixed reaction to earnings reports, with the last quarter beating estimates by $0.18 and resulting in a 0.69% share price increase. Over the last year, EYPT shares have surged by 872.12%, indicating strong investor confidence. The upcoming earnings report and guidance will be crucial for future stock performance.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:01 pm

OPTN

OptiNose (NASDAQ:OPTN) is scheduled to release its quarterly earnings report on March 7, 2024, with an expected EPS of $-0.09. Analysts and investors are keen on not just the earnings beat but also the company's guidance for future growth. Historically, OptiNose has had a mixed performance in beating EPS estimates, with a notable increase in share price following last quarter's earnings beat. Shares have been trading at $1.725 as of March 5, showing a 1.72% increase over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:01 pm

ELUT

Elutia (NASDAQ:ELUT) is scheduled to release its quarterly earnings report on March 7, 2024, with an estimated EPS of $-0.28. Analysts and investors are keen on whether Elutia will surpass this estimate and provide positive guidance for the next quarter. Historical data shows Elutia's stock price reacts significantly to earnings performance and guidance. Last quarter, Elutia beat the EPS estimate, resulting in an 11.64% stock price increase. Over the past year, Elutia's shares have declined by 14.36%.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:01 pm

CECO

CECO Environmental (NASDAQ:CECO) received diverse analyst ratings in the last three months, with a shift towards bullish perspectives. Four analysts have updated their ratings, all raising their price targets, leading to an average 12-month price target of $26.5, up 13.98% from the previous $23.25. The company's financial performance shows strong growth, with a revenue increase of 37.8% as of September 30, 2023, and surpasses industry standards in net margin, ROE, and ROA, while maintaining a lower debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:01 pm

DLTH

Duluth Holdings (NASDAQ:DLTH) is scheduled to release its quarterly earnings report on March 7, 2024, with an expected EPS of $0.27. Despite past earnings misses and a 36% decline in share price over the last year, investors are hopeful for positive guidance. Historical performance shows mixed reactions to earnings reports, with the stock price sometimes increasing despite misses.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 7:01 pm